Facebook
Twitter
LinkedIn
Forward
Making Strides in HIV: Optimizing Treatment Selections and Switch Strategies
Infectious disease specialists W. David Hardy, MD, AAHIVS, and David Alain Wohl, MD, explore ways to optimize therapy selections and switch strategies in the treatment of persons living with HIV infection (PLWH), including considerations for treating PLWH in a pandemic landscape. Topics include current and ongoing disparities in HIV treatment, with strategies to overcome them, an introduction to the rapid initiation of antiretroviral therapy (ART), clinical trial data on the use of 2- and 3-drug ART regimens, an exploration of the uses of long-acting injectable ART, the use of shared decision-making to engage PLWH in treatment decisions, and suggestions on how to optimize treatment outcomes for PLWH. Case studies are discussed to examine how to apply these principles to common clinical scenarios, including overcoming pill fatigue and addressing barriers in treatment-naïve individuals.
Target Audience
HIV specialists and infectious disease specialists, plus other physicians with an interest in HIV care, including primary care physicians and emergency medicine physicians.
Learning Objectives
- Examine the results from recent trials on 2-drug regimens vs 3-drug regimens for HIV, including efficacy, tolerability, and safety
- Compare and contrast the latest evidence regarding new and emerging antiretroviral therapy options for treatment-naïve and treatment-experienced patients
- Identify those patients who would benefit from new and emerging 2-drug regimens, including long-acting injectable antiretroviral therapy
- Develop personalized treatment strategies for patients with HIV based on patient-specific factors and in alignment with the latest evidence
Additional Information
W. David Hardy, MD, AAHIVS
Scientific and Medical Consultant
Adjunct Clinical Professor of Medicine
Division of Infectious Diseases
Keck School of Medicine of USC
Los Angeles, California
W. David Hardy, MD, AAHIVS, discloses the following:
Advisory Board: Gilead Sciences, Merck & Co., ViiV Healthcare
Consultant: Enochian BioSciences
David Alain Wohl, MD
Professor of Medicine
Division of Infectious Diseases
Site Leader, HIV Prevention and Treatment Clinical Trials Unit at Chapel Hill
University of North Carolina School of Medicine
Co-Lead, UNC Viral Hemorrhagic Fever Research Working Group
Chapel Hill, North Carolina
David Alain Wohl, MD, discloses the following:
Advisory Board: Gilead Sciences, Janssen Therapeutics, Merck & Co., ViiV Healthcare
Consultant: Gilead Sciences
Research Support: Gilead Sciences, Janssen Therapeutics, Merck & Co., ViiV Healthcare
Conflicts of Interest Disclosure Policy
It is the policy of the Annenberg Center for Health Sciences to ensure fair balance, independence, objectivity, and scientific rigor in all programming. All faculty and planners participating in accredited education activities are expected to identify and reference off-label product use and disclose any relationship with those supporting the activity or any others with products or services available within the scope of the topic being discussed in the educational presentation.
The Annenberg Center for Health Sciences assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CE/CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by the Annenberg Center for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Annenberg Center is committed to providing its learners with high-quality CE/CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
Accredited Provider Disclosure
Staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.
Planners’ and Managers’ Disclosures
Eugene Cullen, MD (Peer Reviewer)
No significant relationships to disclose.
Jessica Martin, PhD (Medical Writer)
No significant relationships to disclose.
Disclosure of Unlabeled Use
The faculty for this enduring activity has disclosed that there will be discussion about the use of products for non-FDA approved indications.
Disclaimer
The ideas and opinions presented in this educational activity are those of the faculty and do not necessarily reflect the views of the Annenberg Center and/or its agents. As in all educational activities, we encourage practitioners to use their own judgment in treating and addressing the needs of each individual patient, taking into account that patient's unique clinical situation. The Annenberg Center disclaims all liability and cannot be held responsible for any problems that may arise from participating in this activity or following treatment recommendations presented.
Accredited Provider
This activity is provided by The Annenberg Center for Health Sciences at Eisenhower.
AMA PRA Category 1 CreditTM
Accreditation Statement
The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation Statement
The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 2.00 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Available Credit
- 2.00 AMA PRA Category 1 Credit™
This course is offered through myCME.
To take this course you will be redirected to myCME's website. You must login or create an account with myCME in order to complete this activity.
Mocingbird works to provide curated, high quality content to our users. Have a suggestion? Want to partner with us? Get in touch